NRL-2 is being developed as an acute rescue therapy for patients with anxiety who suffer from debilitating acute anxiety episodes, such as panic attacks.*
NRL-2 is a proprietary formulation of intranasal benzodiazepine utilizing Neurelis' technology platform.
NRL-2 is in the initial (formulation) stage of development and presents a worldwide commercial opportunity for Neurelis.
*NRL-2 is a drug candidate being developed for children and adults who require intermittent use of benzodiazepines for acute anxiety episodes and has not been approved by FDA for any indication.